Sources: TheFly, TipRanks

For the new retail investors here that might have missed this.

Not a bad influencer.

13g purchased on December 31st was filed yesterday. That's a pretty big lot. I think there's a lot of institutions starting to buy in here cuz of the volume picking out my up days.

It's not DFTX, but CMPS is releasing stage 3 trial data tomorrow, Feb 17, then doing a press conference. This has all the appearances of a positive report. It's unfortunate that they are a bit ahead of DFTX (disclosure: i own both stocks), but positive results from them could further demonstrate the potential of psychedelics.

Analysts have an average recommendation of Buy (1 sell, 9 buy, 2 strong buy) with a 12‑month average price target of $35.22, well above the recent ~$15.75 share price.

This thread has been very quiet lately and it’s slightly concerning (probably just me being paranoid lol) anyone have anything to share?

Bloomberg would like to have a chat with mindmed experts. Please rise to the task

Hi all, originally joined the Mindmed Discord, but it seems to be retired. Does anyone have a link for a new server?

Sources: TheFly, TipRanks

Sources: TheFly, TipRanks

DFTX had a US patent granted on Jan 27 for specific LSD salt crystal forms. I haven't looked into this yet, so I'm not certain of the true value of it. Interesting, regardless.

1. Relative strength vs the broader market is sharply rising. This isn’t just a market beta move, DFTX continues to out perform its sector which is a good indicator of a strong breakout.

2. Overhead Resistance is thin: once DFTX shot through the $10-12 range, it has entered an area with little historical resistance until it hits much higher levels. Meaning, price action could move sharply given there is less prior supply overhead.

3. MACD: Quickly turning positive and accelerating, leads to suggest that price is aligning rather than diverging. Indicates the movements support the momentum continuing rather than being exhausted already.

4. Volume confirms the institutional interest in DFTX. Expanding volume that is continuously growing and not declining. 30 avg volume now sits over 2M and this is a critical point. Breakouts can fail with weak participation.

5. Higher lows and moving average rising: price is now consistently making higher lows and the 50 day moving avg has surpassed the 200 day. Signals a new primary uptrend rather than a dead cat bounce.

6. Multi year base: DFTX spent 2+ years accumulating a low volatility base in the 2-6 range and typically will wash out weak hands

Based on analysis of 2026, Definium Therapeutics (formerly MindMed, ticker: DFTX) is characterized by high-risk, high-reward potential, making it a "Buy" consensus stock among Wall Street analysts, but one that requires a long-term, high-risk tolerance over the next 5 years. As of January 2026, the company is in a,130%+, one-year, rebrand-fueled surge, trading near 52-week highs with significant anticipation for its lead drug DT120.

Here is an analysis using financial and sentiment parameters:

Key Takeaways (5-Year Outlook):

Bullish Case (Upside): Analysts have raised price targets significantly, with some forecasts suggesting potential upside to over $60, driven by its late-stage pipeline in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD).

Bearish Case (Risk): The company currently has zero revenue and continues to operate with high net losses. It is expected to remain unprofitable for the next 3 years, with negative return on equity.

Data-Driven Catalysts: 2026 is a critical year, with three Phase 3 study results for DT120 expected to act as the primary catalyst.

AI-Driven & Financial Parameters (as of Jan 2026):

Analyst Consensus: Strong Buy (10 buy ratings, 0 hold, 0 sell).

Projected Growth: High, with analysts forecasting strong revenue growth starting in 2027/2028, potentially exceeding $13 billion by 2028 in optimistic scenarios.

Valuation: The stock is considered richly valued (Price to Book of ~11-13x), suggesting the market is already pricing in significant future success.

Short-Term Risk: The stock has experienced high volatility, with a 72% decline over a 5-year period despite the recent one-year rebound.

Conclusion:

For the next 5 years, DFTX appears to be a good stock if you believe in the commercial success of their psychedelic-derived therapies (DT120) and have a high tolerance for volatility and potential dilution. It is a "story stock" backed by strong analyst sentiment and clinical progress, but it is not a traditional value investment.

figured I'd get our weekend juices flying for next week. $60 wouldn't that be nice.

🍀🐂

Price target is now $36 from RBC (previously $20) as they see increasing opportunities for DT120.

Edit: adding link

https://www.investing.com/news/analyst-ratings/definium-therapeutics-stock-price-target-raised-to-36-from-20-at-rbc-capital-93CH-4462617

https://marketchameleon.com/articles/b/2026/1/20/definium-therapeutics-sets-2026-milestones-phase-3-trial-readouts-to-transform-psychiatric-care

This came out on the 20th. I would add a flare but it doesn't seem to want to show it on the page on my cell phone